These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 35661944)

  • 21. Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
    Zhou C; Srivastava MK; Xu H; Felip E; Wakelee H; Altorki N; Reck M; Liersch R; Kryzhanivska A; Oizumi S; Tanaka H; Hamm J; McCune SL; Bennett E; Gitlitz B; McNally V; Ballinger M; McCleland M; Zou W; Das Thakur M; Novello S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37903590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
    J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate.
    Kim JM; Kim B; Kim E; Jang M; Cho JH; Lee HS; Kwak Y; Huang L; Krishnan R; Bai SY; Mounawar M; Kim KM
    Mol Diagn Ther; 2022 Nov; 26(6):679-688. PubMed ID: 36125657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.
    Batenchuk C; Albitar M; Zerba K; Sudarsanam S; Chizhevsky V; Jin C; Burns V
    J Clin Pathol; 2018 Dec; 71(12):1078-1083. PubMed ID: 30275099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
    Vainer G; Huang L; Emancipator K; Nuti S
    PLoS One; 2023; 18(6):e0285764. PubMed ID: 37267266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
    Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
    Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
    Gadgeel S; Hirsch FR; Kerr K; Barlesi F; Park K; Rittmeyer A; Zou W; Bhatia N; Koeppen H; Paul SM; Shames D; Yi J; Matheny C; Ballinger M; McCleland M; Gandara DR
    Clin Lung Cancer; 2022 Jan; 23(1):21-33. PubMed ID: 34226144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
    Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
    Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Harmonization of programmed death-ligand 1 immunohistochemistry and mRNA expression scoring in metastatic melanoma: a multicentre analysis.
    Darmon-Novello M; Adam J; Lamant L; Battistella M; Ortonne N; Balme B; de la Fouchardière A; Chaltiel L; Gerard E; Franchet C; Vergier B
    Histopathology; 2022 Jun; 80(7):1091-1101. PubMed ID: 35322452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
    Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
    Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma.
    Naso JR; Wang G; Banyi N; Derakhshan F; Shokoohi A; Ho C; Zhou C; Ionescu DN
    Ann Diagn Pathol; 2021 Feb; 50():151590. PubMed ID: 33157383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types.
    Maule JG; Clinton LK; Graf RP; Xiao J; Oxnard GR; Ross JS; Huang RSP
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer.
    Noske A; Ammann JU; Wagner DC; Denkert C; Lebeau A; Sinn P; Kreipe HH; Sommer U; Baretton G; Steiger K; Kiechle M; Hieke-Schulz S; Flores M; Roth W; Weichert W
    Histopathology; 2021 Mar; 78(4):567-577. PubMed ID: 32936950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
    Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; West WW; Wu H; Roden AC; Fujimoto J; Yu H; Anders R; Kowalewski A; Rivard C; Rehman J; Batenchuk C; Burns V; Hirsch FR; Wistuba II
    JAMA Oncol; 2017 Aug; 3(8):1051-1058. PubMed ID: 28278348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
    Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
    PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection.
    Munari E; Querzoli G; Brunelli M; Marconi M; Sommaggio M; Cocchi MA; Martignoni G; Netto GJ; Caliò A; Quatrini L; Mariotti FR; Luchini C; Girolami I; Eccher A; Segala D; Ciompi F; Zamboni G; Moretta L; Bogina G
    Front Immunol; 2022; 13():954910. PubMed ID: 35967344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC).
    Wang X; He J; Li J; Wu C; Yue M; Niu S; Jia Y; Jia Z; Cai L; Liu Y
    J Cancer Res Clin Oncol; 2024 Jan; 150(2):43. PubMed ID: 38280970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform.
    Neuman T; London M; Kania-Almog J; Litvin A; Zohar Y; Fridel L; Sandbank J; Barshak I; Vainer GW
    J Thorac Oncol; 2016 Nov; 11(11):1863-1868. PubMed ID: 27664534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer.
    Yu SL; Hsiao YJ; Cooper WA; Choi YL; Avilés-Salas A; Chou TY; Coudry R; Raskin GA; Fox SB; Huang CC; Jeon YK; Ko YH; Ku WH; Kwon GY; Leslie C; Lin MC; Lou PJ; Scapulatempo-Neto C; Mendoza Ramírez S; Savelov N; Shim HS; Lara Torres CO; Cunha IW; Zavalishina L; Chen YM
    Pathology; 2023 Feb; 55(1):19-30. PubMed ID: 36319485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays.
    Klempner SJ; Cowden ES; Cytryn SL; Fassan M; Kawakami H; Shimada H; Tang LH; Wagner DC; Yatabe Y; Savchenko A; Salcius J; Johng D; Chen J; Montenegro G; Moehler M
    JCO Precis Oncol; 2024 Jun; 8():e2400230. PubMed ID: 38822761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.